PMGC HOLDINGS INC. Accretion Expense
PMGC HOLDINGS INC. (ELAB) reported Accretion Expense of $616.29 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2026-08-14
- PMGC HOLDINGS INC. accretion expense for the quarter ending 2026-06-30 was $342.64K.
- PMGC HOLDINGS INC. accretion expense for the quarter ending 2026-03-31 was $273.66K.
- PMGC HOLDINGS INC. accretion expense for the quarter ending 2025-12-31 was $124.10K.
- PMGC HOLDINGS INC. accretion expense for the quarter ending 2025-09-30 was -$3.02K.
- PMGC HOLDINGS INC. accretion expense for fiscal 2025 was $130.77K.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $342.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $616.29K 10-Q · filed 2026-08-14 | $740.39K derived: sum of 3 quarters · filed 2026-08-14 | $737.38K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $273.66K 10-Q · filed 2026-05-15 | $397.75K derived: sum of 2 quarters · filed 2026-05-15 | $394.74K derived: sum of 3 quarters · filed 2026-05-15 | |
| 2025-12-31 | $124.10K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $121.08K derived: sum of 2 quarters · filed 2026-03-30 | $130.77K 10-K · filed 2026-03-30 | |
| 2025-09-30 | -$3.02K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $6.67K 10-Q · filed 2025-11-14 | ||
| 2025-06-30 | $9.68K 10-Q · filed 2025-08-13 | |||
| 2024-06-30 | $42.31K 10-Q · filed 2025-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B |